Form 4: Roivant Sciences Director Melissa Epperly Receives Stock Award

Director Melissa Epperly received 1,613 common shares of Roivant Sciences Ltd. as part of the company's Non-Employee Director Compensation Plan.

Summary

• Melissa Epperly, a director of Roivant Sciences Ltd., received 1,613 common shares on October 21, 2024.
• The shares were awarded under the company's Non-Employee Director Compensation Plan and were fully vested on the grant date.
• Following the transaction, Epperly directly owns 38,037 common shares of Roivant Sciences Ltd.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a standard compensation practice. It indicates confidence in the company's future, as stock awards align director interests with shareholder value.

Positives

• The stock award to a director aligns their interests with those of the shareholders.
• The shares being fully vested upon grant suggests immediate alignment and commitment.

Industry Context

Stock awards are a common form of compensation for non-employee directors, aligning their interests with the long-term performance of the company. This practice is widespread across the pharmaceutical and biotechnology industries.

Comparison to Industry Standards

• Director compensation packages vary widely across the pharmaceutical industry, but stock awards are a common component.
• Companies like Pfizer, Johnson & Johnson, and Novartis also utilize stock awards as part of their director compensation plans.
• The size of the award is relatively small, suggesting it is a routine part of the director's compensation.

Stakeholder Impact

• The stock award aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit shareholder value.

Key Dates